Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease

被引:0
作者
Hisashi Hirayama
Yasuhiro Morita
Takayuki Imai
Kenichiro Takahashi
Atsushi Yoshida
Shigeki Bamba
Osamu Inatomi
Akira Andoh
机构
[1] Shiga University of Medical Science,Department of Medicine
[2] Ofuna Chuo Hospital,Center for Gastroenterology and Inflammatory Bowel Disease
来源
BMC Gastroenterology | / 22卷
关键词
Ustekinumab; Therapeutic drug monitoring; Enteroscopy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 233 条
[1]  
Baumgart DC(2012)Crohn's disease Lancet 380 1590-1605
[2]  
Sandborn WJ(2010)Inflammatory bowel disease Annu Rev Immunol 28 573-621
[3]  
Kaser A(2010)The natural history of adult Crohn's disease in population-based cohorts Am J Gastroenterol 105 289-297
[4]  
Zeissig S(2021)Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 J Gastroenterol 56 489-526
[5]  
Blumberg RS(2017)Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials Aliment Pharmacol Ther 45 1291-1302
[6]  
Peyrin-Biroulet L(2004)IL-12 and IL-23: master regulators of innate and adaptive immunity Immunol Rev 202 96-105
[7]  
Loftus EV(2019)IL-23 in inflammatory bowel diseases and colon cancer Cytokine Growth Factor Rev 45 1-8
[8]  
Colombel JF(2010)Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab J Mol Biol 402 797-812
[9]  
Sandborn WJ(2008)A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease Gastroenterology 135 1130-1141
[10]  
Nakase H(2012)Ustekinumab induction and maintenance therapy in refractory Crohn's disease N Engl J Med 367 1519-1528